Wesley Sukdao
Cambridge, England, United Kingdom
2K followers
500+ connections
View mutual connections with Wesley
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
View mutual connections with Wesley
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
About
Championing a first-in-class molecular platform to quantitatively detect disease earlier…
Education
Languages
-
English
Full professional proficiency
View Wesley’s full profile
Other similar profiles
-
Adam Gazzoli
LondonConnect -
Robert Johnson
United KingdomConnect -
Colin Griffith
Previously Consultant - Precious Metals at London Metal Exchange
Walton On The HillConnect -
Andrew Powell
Renovating property.
CrowleConnect -
Michael Duke
LondonConnect -
Gavin V.
Consultant at i-Search
LondonConnect -
Jonathan Mealey
Chief Executive Officer at Sigma Treasury
Greater LondonConnect -
Dee Dervish
Head of EMEA Cleared Derivatives Practice
LondonConnect -
Amy Middleton
Experienced currency professional looking for my next opportunity
LondonConnect -
Ozgur Gul
LondonConnect -
Jonathan Cowan (JC)
LondonConnect -
Milan Shah
Engagement Director, Strategic Accounts (Advisory) at Tata Consultancy Services.
LondonConnect -
Aaron Grantham
LondonConnect -
Fred Cleary
Pegasus Capital LLP
WatfordConnect -
Johan JOLY
London Area, United KingdomConnect -
Martti Siivola
FX and Compliance Consultant
Greater LondonConnect -
John Marley
United KingdomConnect -
Gino Bellato
LisbonConnect -
Paul Johnstone
Principal Consultant at Syncordis
LondonConnect -
Wilhelm Beller
Digital Assets & Capital Markets I Web 3.0 I Fintech I Arrington Capital
LondonConnect
Explore more posts
-
Richard Atkins
https://lnkd.in/e3SUw5WV We know how important clinical validation is when it comes to biomarker developments, diagnostic assay developments and more over understanding disease development research. Biospecimens have always been used in the forefront of such developments but has remained a key challenge in terms of ethical and faster accessibility when it comes to disease state or targeted demographic clinical sample collection. 2BScientific Ltd. have joined hands with Medix Biochemica to make the process easier, reliable, and efficient in terms of offering a wide range of biospecimens from not just plasma, serum, but also non-traditional specimens like faecal matter, cerebrospinal fluids, clinical swabs, sputum from individuals with rare disease that are usually hard to obtain. Let’s take your research potential a step forward in unlocking new insights, speak with our product specialist today NAYANI PRAMANIK (PhD) #biospecimens #clinicalvalidation #hereforyou #2bscientific
16
2 Comments -
Andrew Welsh
Hi LinkedInVerse, Interested to get people's thoughts on this news story? As many in the Medical Devices, Biotech and Drug Discovery sectors has noticed over the last year, funding/investments have not been released, even when promised and contracts signed. I've noticed a little upturn in roles recently, which hopefully means funding/investments are now being released, is this other people's recent experience? I wish any of the political parties were talking more specifically about this, and hopefully this think tank may make them do this. https://lnkd.in/eizJ6s9Q #Investment #MedicalDevices #Biotech #DrugDiscovery IPPR #TheInstituteforPublicPolicyResearch
2
-
Olga Peycheva
Our new episode it out discussing a very important issue - information clinical trials participants of their genetic testing results. Many companies opt-out and decide not to do it but is that always the best decision? You can learn more in the latest episode. #clinicaltrials #alzheimer
2
-
Liam Taylor
We have a 99.6% failure rate in drug development for neurodegenerative disease. The current model is broken and needs changing. The FDA Modernisation Act 2.0 provides alternatives to existing clinical models to be used as supporting evidence. An iPSC platform if stratified across age, disease mutation, sex and ethnicity would be deployed before in-vivo animal and human testing and would be sized as required to provide statistical credible data for efficacy and approval. the building and validation of this model could achieve the following: 1. Size the addressable opportunity for the treatment ie. What disease mutations will have a positive response given model is stratified for sporadic Alzheimer’s disease. 2. Screen both current and historic compounds, small molecules, therapies etc at scale and in a high throughput environment. AND HERE IS THE REAL KICKER 3. You could power up the number of iPSC patient lines to reduce the number of patients needed to be recruited into a clinical trial BENEFITS Save time, save money, understand sooner patient and public health impact and IMPORTANTLY, improve patient outcomes. Let’s beat the 99.6%! #ipscs #neuroscience #alzheimersresearch #alzheimersdisease #neurodegenerativedisease #research #biopharma #biotech #pharma #drugdiscovery #drugdevelopment #dementia
100
5 Comments -
Michael Jones
How do growth factors produce cell division? Growth factors promote cell proliferation by initiating a chain of events when they bind to their receptors, which ripple through the cell. Our latest blog article explains these events. https://lnkd.in/eSS-qsjS
17
-
Olga Peycheva
Our latest episode is out! You can learn about digital health trends and the chances to find funding in this area. It also covers MHRA and NICE report on digital health solutions in mental health. It is very interesting to hear what users think of digital health applications. #digitalhealth #mentalhealth
-
Duncan Borthwick PhD
Testing out new Chat GPT 4.0... It's remarkably good at summarising and producing structured answers. Hey Chap GTP, What impact do you think iPSCs will have on ALS drug discovery? ChatGPT Induced pluripotent stem cells (iPSCs) are expected to significantly impact amyotrophic lateral sclerosis (ALS) drug discovery in several key ways: Disease Modeling: iPSCs can be generated from patients with ALS and differentiated into motor neurons, the cell type primarily affected by the disease. This allows researchers to create patient-specific models of ALS in the lab. These models are invaluable for studying disease mechanisms and for screening potential drug candidates in a context that closely mimics human pathology. Personalized Medicine: Because iPSCs can be derived from individual patients, they facilitate the study of genetic variability in ALS. Researchers can explore how different genetic mutations contribute to the disease and how patients with different genetic backgrounds respond to treatments. This paves the way for personalized medicine approaches, where treatments can be tailored to the genetic profile of individual patients. High-Throughput Drug Screening: iPSC-derived neurons can be used in high-throughput screening to test thousands of compounds for potential therapeutic effects. This approach can rapidly identify promising drug candidates that can then be further validated in more complex models and eventually in clinical trials. Understanding Disease Mechanisms: iPSCs provide a platform for investigating the cellular and molecular mechanisms underlying ALS. By differentiating iPSCs into various neural cell types, scientists can study the interactions between motor neurons, astrocytes, and other cell types involved in ALS pathology. This comprehensive understanding is crucial for identifying new therapeutic targets. Testing Drug Toxicity and Efficacy: iPSC-derived motor neurons can be used to test the toxicity and efficacy of drug candidates before they enter clinical trials. This helps ensure that only the most promising and safest drugs move forward in the drug development pipeline, potentially reducing the time and cost associated with bringing new therapies to market. In summary, iPSCs offer a versatile and powerful tool for ALS drug discovery. They enable the creation of disease models that closely replicate human pathology, facilitate personalized medicine, support high-throughput drug screening, improve our understanding of disease mechanisms, and offer new avenues for testing drug safety and efficacy. These advantages collectively accelerate the pace of discovery and increase the likelihood of finding effective treatments for ALS. #ipscs #chatgpt
30
2 Comments -
Joshua Berlin
A sobering assessment of London’s AIM market from my BioCentury Inc. colleague Stephen Hansen, following the recent de-listings of three U.K. biotechs. 💬 “Anybody who lists on AIM should not be surprised that there’s low liquidity and they can’t raise secondary financing.” - Tim Haines of Abingworth 💬 ✅ Full analysis: https://lnkd.in/d5VNEEKG #biotech #capitalmarkets
5
-
Shannon Eaker
Glucose transporter 1 (GLUT1) overexpression has been in the news by Crystal Mackall (https://lnkd.in/eFFb74Wp) and Michel Sadelain (https://lnkd.in/eZ4fN9ya). This has shown to increase #potency and #persistence by altering the cells metabolic pathways. Did you know that a simple method to increase GLUT1 expression for #cellandgenetherapy is altering the cell culture environment (mimicking #TME)? It also increases their persistent tumor killing capacity (https://lnkd.in/esAiqeV4). xcellbio bioreactor and Cytek Biosciences spectral FC analysis.
56
3 Comments -
Erin Blank
~ UK Biotech Funding Update - October 2024 ~ Big wins this week 🥳 Resolution Therapeutics raised £63.5M in Series B, led by Syncona Limited , to advance macrophage-based cell therapies for liver disease into clinical trials. Enara Bio secured $32.5M in Series B to accelerate TCR-based immunotherapies targeting cancer antigens from the "dark genome." LoQus23 Therapeutics Ltd Therapeutics landed £35M in Series A to develop small-molecule treatments for Huntington's disease, targeting DNA repair pathways. It's great to see the UK market picking up momentum with substantial funding rounds in recent weeks (I haven't mentioned them all!). These investments highlight the confidence in novel therapies, especially as companies push toward clinical trials. 2025 looks promising for further growth and breakthroughs in areas such as immunotherapy and gene therapy. Looking forward to seeing how these companies utilise their new resources to advance their ambitious plans!
29
-
Olga Peycheva
Our recent industry meeting inspired me to share my experience with the clinical trials budget and contract process. As always I try to provide some recommendations on how we can improve the process. At the end of the day our patients will be the winners if we can set up clinical trials much quicker. It is always good to have that in mind! #clinicaltrials #budget #contract #UK
4
-
Rachel Smith
As I defrost following the UKs recent icy weather, I have been reflecting on 2024 successes for rare drug development. ✅️ 26 of CDER's 50 novel drug approvals (52%) were to treat rare diseases ✅️ 8 of CBER's 17 biologics licensing application approvals (47%) were to treat rare disease incl. the first CRSPR approval ✅️ 20 marketing authorisations for orphan drugs were finalised by EMA (as of Nov-24) ✅️ Newborn screening increased globally ✅️ Increasing numbers of countries recognised the burden of rare disease and issued research or funding Excited to see where 2025 takes us with the coming technological wave and early signs of returning biotech investment. What are you most excited about in 2025? #rarediseases #raredisease #innovation #innovation2025
63
3 Comments -
Matthew Tong
Here’s an interesting publication detailing how trial efficiency can reshape early-stage development in #biotech... In Phase I studies, every decision affects the development pathway, making trial design and timing critical. By introducing flexibility into these early phases, clinical teams can meet complex study demands without compromising on speed or quality—a balance essential in today’s fast-paced therapeutic field. With streamlined processes, from recruitment through data collection, biotech R&D professionals can better allocate resources, achieve reliable results, and move confidently toward later stages of development. #BiotechR&D #BioTech #BioPharm #EarlyStageDevelopment #ClinicalTrials #TrialEfficiency #DrugDevelopment
3
-
Mark Corbett
Sophie Peresson of the OECD Global Forum SynBio Focus Group gives the next #SynbiTECH2024 plenary presentation, on biosecurity, anticipatory governance, and responsible innovation. She says that the UK has a long history of creating roadmaps and strategy that inform Goverment of the direction of travel, and sets out the future requirements of the sector. The UK Biological Security Strategy is key guidance, and importantly is aligned to US guidelines, helping to drive an international framework for biosecurity. International exchange of information and best practices is crucial to the development of these technologies and supportive policy.
7
-
Stefan Ogrodzinski
New report from London Economics - https://lnkd.in/eG6tmMaZ - highlights how the reduction in R&D tax relief for SMEs, coupled with increased relief for larger companies, risks stifling innovation in sectors where smaller firms play a crucial role. The report calls for a more nuanced, sector-specific approach to evaluating and implementing R&D tax relief which aligns with the need for fundamental changes to better support UK SMEs and foster genuine innovation across all sectors.
12
-
John English, HCCP
It's been a busy week for inspection results. Here we have a domestic EIR for a biologics firm - and this is quite a read, When you see the pdf file, 18 SEP 2023, do not be deceived - it is not 'only 6 pages.' The full EIR is over 94 pages. It will give you a lot of detail beyond the usual 483 and much more context around the observations, Obs. 2 is in the image below and, of course, I picked the CSV / DI one, There are however a large set of observations. Here's the FDAs own summary. "The current inspection covered the firm’s Quality, Production, Materials, Facilities and Equipment, Laboratory Controls, Packaging and Labeling systems. A 5-item Form FDA 483 (Attachment 1) was issued to the firm at the end of the inspection on February 10, 2023, for the following observations: (1). Written records of investigations into unexplained discrepancies, the failure of a batch or any of its components to meet specifications, do not always include the appropriate conclusions and follow-up; (2). The firm has not established adequate procedural controls to protect the electronic data acquisition and manufacturing control systems used for drug substance manufacturing in Building lack of assurance that the firm’s drug substance manufacturing operations in Building at the XXXXXXXX facility; (3). There is a (b) (4) at the XXXXXXXX facility are appropriately designed to ensure the prevention of contamination of equipment or product by environmental and processing conditions that would be expected to have an adverse effect on product quality; (4). Standard Operating procedures or work instructions are not followed or are inadequate. (5). The firm’s quality unit’s oversight of its GMP manufacturing operations is inadequate. " The above made preparing this post so much easier. Here's the link to the full EIR: https://lnkd.in/egUgQdss BUT if you only want the traditional 483, 10 FEB 2023, 'only 16 pages' - go here: https://lnkd.in/ehu-SqQY #fda #biolgoics #CBER #dataintegrity #CGMP #Washington
95
7 Comments -
Martijn Reniers
Are you a manufacturer of Digital Therapeutics (DTx) with a focus on the UK market? In this blog post, we delve into the intricacies of Digital Therapeutics (DTx) regulation in the UK, especially in light of Brexit in January 2020. 👉 https://lnkd.in/eqYb38ZF #DTx #DigitalTherapeutics #RegulatoryAffairs #Brexit
11
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named Wesley Sukdao
1 other named Wesley Sukdao is on LinkedIn
See others named Wesley Sukdao